1. Home
  2. PHIO vs MDCX Comparison

PHIO vs MDCX Comparison

Compare PHIO & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phio Pharmaceuticals Corp.

PHIO

Phio Pharmaceuticals Corp.

HOLD

Current Price

$0.65

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Logo Medicus Pharma Ltd.

MDCX

Medicus Pharma Ltd.

HOLD

Current Price

$1.20

Market Cap

10.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHIO
MDCX
Founded
2003
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1M
10.9M
IPO Year
2011
2025

Fundamental Metrics

Financial Performance
Metric
PHIO
MDCX
Price
$0.65
$1.20
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
★ $32.50
AVG Volume (30 Days)
53.7K
★ 54.5K
Earning Date
11-05-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.70
$1.15
52 Week High
$1.88
$114.00

Technical Indicators

Market Signals
Indicator
PHIO
MDCX
Relative Strength Index (RSI) 27.10 21.39
Support Level N/A N/A
Resistance Level $1.12 $2.16
Average True Range (ATR) 0.07 0.26
MACD -0.01 0.15
Stochastic Oscillator 5.14 11.77

Price Performance

Historical Comparison
PHIO
MDCX

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

About MDCX Medicus Pharma Ltd.

Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.

Share on Social Networks: